BioMarin Pharmaceutical Inc (BMRN) Return on equity 2016–2025
BioMarin Pharmaceutical Inc (BMRN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
5.7%FY2025 · since FY2016: -22.8% → 5.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 5.7% | -1.8 pp |
| FY2024 | 7.5% | +4.2 pp |
| FY2023 | 3.4% | +0.3 pp |
| FY2022 | 3.1% | +4.6 pp |
| FY2021 | -1.5% | -22.3 pp |
| FY2020 | 20.8% | +21.6 pp |
| FY2019 | -0.8% | +1.8 pp |
| FY2018 | -2.6% | +1.6 pp |
| FY2017 | -4.2% | +18.6 pp |
| FY2016 | -22.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BMRN financial trends
BMRN RevenueBMRN Net incomeBMRN Net marginBMRN Gross profitBMRN Gross marginBMRN Operating incomeBMRN Operating marginBMRN Operating cash flowBMRN Free cash flowBMRN Capital expendituresBMRN Stock buybacksBMRN Dividends paidBMRN Total assetsBMRN Total liabilitiesBMRN Shareholders’ equityBMRN overview →